# IQVIA Holdings Inc. (IQV) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $267.77, market value $44.1 billion.

## Valuation
- **P/E (trailing): 33.3×** (5-yr avg 35.9×, 3-yr avg 28.9×). IQVIA Holdings Inc. trades at 33.3× trailing earnings, close to its own five-year average of 35.9×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 18.5×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 3.96**. A PEG of 3.96 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 2.6×**. Each dollar of revenue is priced at 2.6×.
- **Price / book: 7.1×**. The shares trade at 7.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 17.1×**. Enterprise value is 17.1× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.0%** (5-yr avg 4.6%). Free cash flow equals 5.0% of the market value, in line with its five-year average of 4.6%.
- **Earnings yield: 3.0%**. The inverse of the P/E: 3.0% of the price is earned each year.

## Profitability
- **Operating margin: 13.3%**. 13.3% of revenue is left after running the business.
- **Net margin: 8.3%**. 8.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 20.9%**. 20.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 8.8%**. Return on all capital, debt included, is 8.8%.
- **Return on assets: 4.6%**. Each dollar of assets produces 4.6% of profit.

## Growth
- **Revenue growth (1 yr): 5.9%** (3-yr 4.2%/yr, 5-yr 7.5%/yr). Revenue grew 5.9% over the last year, against 7.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 4.7%** (3-yr 11.1%/yr, 5-yr 40.5%/yr). Earnings per share rose 4.7%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 8.9%/yr**. Free cash flow has compounded at 8.9% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 2.42**. Debt is 2.42 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 4.1×**. It would take 4.1 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 2.22**. A Z-score of 2.22 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. IQVIA Holdings Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (18 analysts). 18 analysts cover IQVIA Holdings Inc.; the consensus is strong_buy, with an average price target of $276.28 (+3% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 45.5%** (YTD 18.8%, 3-mo 46.0%). The shares are up 45.5% over twelve months including dividends.
- **From 52-week high: -1.5%** (73.3% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 70**. An RSI of 70 is neutral.
- **Beta (1 yr): 0.84** (volatility 41%). Beta of 0.84 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IQV · Page: https://foliofundamentals.com/stocks/iqv

Not investment advice.